COMPARE · Data as of August 21, 2026
ADMA vs PAHC
Verdict: Side-by-side breakdown using the Bull Rankings model. ADMA scored 81.3, PAHC scored 72.1 — ADMA leads.
Compare another set
ADMA
ADMA Biologics, Inc.
81.3
$9.84 · $2.2B
fundamentals as of
Score gap
9.2
ADMA leads
PAHC
Phibro Animal Health Corp
72.1
$36.32 · $1.5B
At a glance · who leads each dimension, on the model's own rules
- CheapestADMA14.1x
- Fastest growthPAHC+26.0%
- Strongest balance sheetADMA1.11
- Highest qualityADMA84 / 100
- Largest discount to fair valueADMA-32%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ADMA
stronger →← stronger
PAHC
84
Qualityreturns · margins · balance sheet
61
77
Growthrevenue & earnings expansion
86
83
Valuevaluation vs sector peers
71
ADMA is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ADMA
PAHC
$116mC
FCF
$13mC-
+8.0%B
Rev
+26.0%A-
1.11C
D/E
2.52D+
14.1xA-
P/E
14.5xB+
0.60A-
PEG
—
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADMA
PAHC
32% below
Price vs fair valuelower is cheaper
391% above
~4%/yr
Growth the price implies10-yr FCF · lower = less priced in
~59%/yr
+14%
1-yr DCF upside
-85%
+47%
5-yr DCF upside
-80%
+117%
10-yr DCF upside
-70%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADMA
Why this score
- Buying back stock
- Durable high returns
- Earnings outpace cash
PAHC
No notable signals flagged.
The companies
ADMAADMA Biologics, Inc.
Why now
Biotechnology · market cap $2.2b. Down 52% from 52-week high of $20.46 — deep drawdown territory. PEG 0.60 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $17.00 (implying +73% upside).
Moat
Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
PAHCPhibro Animal Health Corp
Why now
Pharmaceuticals · market cap $1.5b. Down 40% from 52-week high of $60.08 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory.
Moat
ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.52 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 40% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ADMA and PAHC diverge
On the headline score the gap is 9.2 points in favor of ADMA. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityADMA 84.1 · PAHC 61.3ADMA +22.8
- ValueADMA 83.0 · PAHC 71.4ADMA +11.6
- GrowthADMA 76.9 · PAHC 85.6PAHC +8.7
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.